Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy

References

• Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273–293.
   PubMed Web of Science ®Google Scholar
• Norata GD, Tavori H, Pirillo A, et al. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res. 2016 Oct;112(1):429–442.
   PubMed Web of Science ®Google Scholar
• Han B, Eacho PI, Knierman MD, et al. Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res. 2014 Jul;55(7):1505–1514.
   PubMed Web of Science ®Google Scholar
• Nishikido T, Ray KK. Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries. Front Cardiovasc Med. 2018;5:199.
   PubMed Web of Science ®Google Scholar
• Lipari MT, Li W, Moran P, et al. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem. 2012 Dec 21;287(52):43482–43491.
   PubMed Web of Science ®Google Scholar
• Essalmani R, Susan-Resiga D, Chamberland A, et al. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem. 2011 Feb 11;286(6):4257–4263.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009 Jul;94(7):2537–2543.
   PubMed Web of Science ®Google Scholar
• Persson L, Cao G, Stahle L, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2666–2672.
   PubMed Web of Science ®Google Scholar
• Boyer M, Mitchell PL, Poirier P, et al. Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia. Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E460–E468.
   PubMed Web of Science ®Google Scholar
• Krysa JA, Ooi TC, Proctor SD, et al. Nutritional and lipid modulation of PCSK9: effects on cardiometabolic risk factors. J Nutr. 2017 Apr;147(4):473–481.
   PubMed Web of Science ®Google Scholar
• Rannikko J, Jacome Sanz D, Ortutay Z, et al. Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. J Intern Med. 2019 Nov;286(5):553–561.
   PubMed Web of Science ®Google Scholar
• Baragetti A, Grejtakova D, Casula M, et al. Proprotein convertase subtilisin-kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps. Pharmacol Res. 2018 Apr;130:1–11.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003 Jun;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005 Feb;37(2):161–165.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis. 2014 Nov;237(1):76–81.
   PubMed Web of Science ®Google Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration. Eur Heart J. 2018 Jul 14;39(27):2540–2545.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Chapman MJ, Stock JK, et al. New prospects for PCSK9 inhibition? Eur Heart J. 2018 Jul 14;39(27):2600–2601.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013 May;228(1):18–28.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Teoh H, Kallend D, et al. Inclisiran Lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019 Jan;42(1):173–176.
   PubMed Web of Science ®Google Scholar
• Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010 May 17;5(5):e10682.
   PubMed Web of Science ®Google Scholar
• Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2011 Jan;24(1–2):3–9.
   PubMed Web of Science ®Google Scholar
• Li W, Ward FR, McClure KF, et al. Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule. Nat Struct Mol Biol. 2019 Jun;26(6):501–509.
   PubMed Web of Science ®Google Scholar
• Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice. Eur Heart J. 2017 Aug 21;38(32):2499–2507.
   PubMed Web of Science ®Google Scholar
• Stadler SL, Cook TJ. PCSK9 inhibitors and managing cost in the managed care setting. Am J Manag Care. 2017 Jun;23(9 Suppl):S149–s155.
   PubMed Web of Science ®Google Scholar
• Ly K, Saavedra YG, Canuel M, et al. Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J Biol Chem. 2014 Jun 20;289(25):17732–17746.
   PubMed Web of Science ®Google Scholar
• Masuda Y, Yamaguchi S, Suzuki C, et al. Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies, DS-9001a, albumin binding domain-fused anticalin protein. J Pharmacol Exp Ther. 2018 May;365(2):368–378.
   PubMed Web of Science ®Google Scholar
• Mitchell T, Chao G, Sitkoff D, et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412–424.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):431–438.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008 Jan 25;283(4):2363–2372.
   PubMed Web of Science ®Google Scholar
• Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1448–1453.
   PubMed Web of Science ®Google Scholar
• Sun H, Samarghandi A, Zhang N, et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585–1595.
   PubMed Web of Science ®Google Scholar
• Rashid S, Tavori H, Brown PE, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014 Jul 29;130(5):431–441.
   PubMed Web of Science ®Google Scholar
• Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454–1459.
   PubMed Web of Science ®Google Scholar
• Bjermo HID, Jullberg J, Dahlman I, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation on abdominal obesity> a randomized controlled trial. Am J Clin Nutr. 2012;95(5):1003-12
   PubMedGoogle Scholar
• Galland L. Diet and inflammation. Nutr Clin Pract. 2010 Dec;25(6):634–640.
   PubMed Web of Science ®Google Scholar
• Ou J, Tu H, Shan B, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A. 2001;98(11):6027–6032.
   PubMed Web of Science ®Google Scholar
• Cao A, Wu M, Li H, et al. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res. 2011 Mar;52(3):518–530.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ricci C, Macchi C, et al. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem. 2016 Feb 12;291(7):3508–3519.
   PubMed Web of Science ®Google Scholar
• Persson L, Gälman C, Angelin B, et al. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology. 2009 Mar;150(3):1140–1146.
   PubMed Web of Science ®Google Scholar
• H DB L, Park SW, Lee HS, et al. Hepatocyte nuclear factor1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natura hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885–28895.
   PubMed Web of Science ®Google Scholar
• Tao R, Xiong X, DePinho RA, et al. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013 Oct 11;288(41):29252–29259.
   PubMed Web of Science ®Google Scholar
• Ai D, Chen C, Han S, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. 2012 Apr;122(4):1262–1270.
   PubMed Web of Science ®Google Scholar
• Li H, Liu J. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem J. 2012 May 1;443(3):757–768.
   PubMedGoogle Scholar
• Glerup S, Schulz R, Laufs U, et al. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. Basic Res Cardiol. 2017 May;112(3):32.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013;7:1135–1148.
   PubMed Web of Science ®Google Scholar
• Khan AR, James MN. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 1998;7(4):815–836.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mamarbachi M, Chen WT, et al. GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Rep. 2015 Dec 15;13(10):2064–2071.
   PubMed Web of Science ®Google Scholar
• Miller EA, Beilharz TH, Malkus PN, et al. Multiple cargo binding sites on the COPII subunit Sec24p ensure capture of diverse membrane proteins into transport vesicles. Cell. 2003 Aug 22;114(4):497–509.
   PubMed Web of Science ®Google Scholar
• Chen XW, Wang H, Bajaj K, et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife. 2013 Apr 9;2:e00444.
   PubMed Web of Science ®Google Scholar
• Gustafsen C, Kjolby M, Nyegaard M, et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 2014 Feb 4;19(2):310–318.
   PubMed Web of Science ®Google Scholar
• Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008 Nov 14;283(46):31791–31801.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(5):633–643.
   PubMed Web of Science ®Google Scholar
• Khoury E, Brisson D, Gaudet D. Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opin Drug Discov. 2020 Apr;15(4):403-414.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928–933.
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100–7105.
   PubMed Web of Science ®Google Scholar
• Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9820–9825.
   PubMed Web of Science ®Google Scholar
• Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012 Dec;53(12):2515–2524.
   PubMed Web of Science ®Google Scholar
• Manniello M, Pisano M. Alirocumab (Praluent): first in the new class of PCSK9 inhibitors. P T. 2016;41(1):28–53.
   PubMedGoogle Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769–779.
   PubMed Web of Science ®Google Scholar
• Rise P, Tragni E, Ghezzi S, et al. Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly. Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):215–220.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2531–2540.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019 Oct 29;74(17):2132–2146.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012 Dec 8;380(9858):2007–2017.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–2353.
   PubMed Web of Science ®Google Scholar
• Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13;126(20):2408–2417.
   PubMed Web of Science ®Google Scholar
• Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29–36.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995–2006.
   PubMed Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012 Dec 19;308(23):2497–2506.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500–1509.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28;390(10106):1962–1971.
   PubMed Web of Science ®Google Scholar
• Sabatine M Clinical benefit of evolocumab in patients with a story of MI: an analysis from FOURIER;. Presented at: American Heart Association 2017 Scioentific Session; 2017 November 13; Anaheim, CA.
   Google Scholar
• Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018 Jan 23;137(4):338–350.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017 Apr 20;376(16):1527–1539.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809–1819.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–2548.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758–769.
   PubMed Web of Science ®Google Scholar
• Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020 Mar 26;58(4):496–517.
   PubMed Web of Science ®Google Scholar
• Julius U, Tselmin S, Schatz U, et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019 April 01;14(S1):45–50.
   PubMedGoogle Scholar
• Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017 Apr 20;376(16):1517–1526.
   PubMed Web of Science ®Google Scholar
• Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017 Apr 20;376(16):1589–1590.
   PubMed Web of Science ®Google Scholar
• Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, low-density lipoprotein cholesterol, and neurocognitive impairment: reasons for geographic and racial differences in stroke study (REGARDS). Circulation. 2018 Mar 20;137(12):1260–1269.
   PubMed Web of Science ®Google Scholar
• Colhoun HMGH, Robinson JG, Leiter LA, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in pooled analysis from 10 ODISSEY Phase 3 studies. Eur Heart J. 2016;37:2981–2989.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016 May;4(5):403–410.
   PubMed Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016 Dec 1;375(22):2144–2153.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017 Feb;5(2):97–105.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. JAMA. 2016 Oct 4;316(13):1383–1391.
   PubMed Web of Science ®Google Scholar
• Da Dalt L, Ruscica M, Bonacina F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019 Jan 21;40(4):357–U61.
   PubMed Web of Science ®Google Scholar
• Malvandi AM, Loretelli C, Ben Nasr M, et al. Sitagliptin favorably modulates immune-relevant pathways in human beta cells. Pharmacol Res. 2019 Oct;148:104405.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis.2020 Jan;292:160-162
   Google Scholar
• Arrieta A, Page TF, Veledar E, et al. Economic evaluation of PCSK9 Inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One. 2017;12(1):e0169761.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Penko J, Coxson PG, et al. Updated Cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. Jama. 2017 Aug 22;318(8):748–750.
   PubMed Web of Science ®Google Scholar
• AIFA. The medicines utilisation monitoring centre. National Report on Medicines use in Italy. Italian Medicines Agency; 2018.
   Google Scholar
• Dressel A, Schmidt B, Schmidt N, et al. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: insights from the ludwigshafen risk and cardiovascular health cohort. Vascul Pharmacol. 2019;120: 106566-106566.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 Inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Jama. 2016 Aug 16;316(7):743–753.
   PubMed Web of Science ®Google Scholar
• NICE. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Excellence. NIfHaC, editor. London 2016.
   Google Scholar
• Kwan BC, Kronenberg F, Beddhu S, et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007 Apr;18(4):1246–1261.
   PubMed Web of Science ®Google Scholar
• Fan D, Yancey PG, Qiu S, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008 Feb 12;47(6):1631–1639.
   PubMed Web of Science ®Google Scholar
• Druce I, Abujrad H, Ooi TC. PCSK9 and triglyceride-rich lipoprotein metabolism. J Biomed Res. 2015;29(6):429.
   PubMed Web of Science ®Google Scholar
• Choi S, Aljakna A, Srivastava U, et al. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Dis. 2013 Jul 24;12:112.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hegele RA, Fazio S, et al. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314.
   PubMed Web of Science ®Google Scholar
• Hollstein T, Vogt A, Grenkowitz T, et al. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascul Pharmacol. 2019 May;116:8–15.
   PubMed Web of Science ®Google Scholar
• Kwakernaak AJ, Lambert G, Dullaart RP. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. Clin Biochem. 2014 May;47(7–8):679–682.
   PubMed Web of Science ®Google Scholar
• Dong B, Singh AB, Fung C, et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014;235(2):449–462.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Dasaradhi PV, Mohmmed A, et al. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003 Dec;67(4):657–685.
   PubMed Web of Science ®Google Scholar
• Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014 Dec 10;136(49):16958–16961.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2016;376(1):41–51.
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Munoz Estrella A, Sourlas A, et al. Inclisiran: A new promising agent in the management of hypercholesterolemia. Diseases. 2018 Jul 13;6:3.
   Google Scholar
• Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020 Jan;95(1):77–89.
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519.
   Web of Science ®Google Scholar
• German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs. 2020 Feb 01;34(1):1–9.
   PubMed Web of Science ®Google Scholar
• van Poelgeest EP, Hodges MR, Moerland M, et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 2015 Dec;80(6):1350–1361.
   PubMed Web of Science ®Google Scholar
• Mullard A. Nine paths to PCSK9 inhibition. Nat Rev Drug Discov. 2017 Apr 28;16(5):299–301.
   PubMed Web of Science ®Google Scholar
• Miyosawa K, Watanabe Y, Murakami K, et al. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E177–90.
   PubMed Web of Science ®Google Scholar
• Steneberg P, Lindahl E, Dahl U, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018 Jun 21;3:12.
   Web of Science ®Google Scholar
• Seidah NG, Poirier S, Denis M, et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012;7(7):e41865.
   PubMed Web of Science ®Google Scholar
• Porteus M. Genome editing: a new approach to human therapeutics. Annu Rev Pharmacol Toxicol. 2016 Jan 06;56(1):163–190.
   PubMed Web of Science ®Google Scholar
• Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374–5379.
   PubMed Web of Science ®Google Scholar
• Carreras A, Pane LS, Nitsch R, et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol. 2019;17(1): 4-4. DOI:10.1186/s12915-018-0624-2
   PubMedGoogle Scholar